This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MYOS MYOS RENS Technology (MYOS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About MYOS RENS Technology Stock (NASDAQ:MYOS) 30 days 90 days 365 days Advanced Chart Get MYOS RENS Technology alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.01▼$11.4052-Week Range N/AVolumeN/AAverage Volume1.68 million shsMarket Capitalization$16.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada. Read More Receive MYOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MYOS RENS Technology and its competitors with MarketBeat's FREE daily newsletter. Email Address MYOS Stock News HeadlinesRen Systems Raises $3.5M, Partners With ZoomInfo to Bring AI-powered Relationship Intelligence to Dealmakers at 35,000 BusinessesSeptember 11, 2024 | venturebeat.comVNew Study Evaluates Use of the Nerivio® REN Wearable for Treatment of Migraine in Children Under the Age of 12July 25, 2024 | tmcnet.comBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most investors are still asleep… but not for long. Garrett Goggin’s latest research reveals how you can “front-run” the greatest investor alive by positioning in four small miners sitting on up to 100X potential upside. When this hits the news — it’ll be too late.July 12 at 2:00 AM | Golden Portfolio (Ad)Ren Zhengfei says US government 'underestimates' HuaweiDecember 23, 2023 | bbc.comBBio-active Peptides Market Size 2023-2031 Industrial Trends by Absolute Reports | with [93 Pages]May 11, 2023 | marketwatch.comLatest "Bio-active Peptides Market" Size Forecast 2023-2031: New Challenges, Drivers, and RestraintsMay 8, 2023 | marketwatch.comBio-active Peptides Market Size Dynamics 2023-2029April 13, 2023 | marketwatch.comGlobal Bio-active Peptides Market: Future Extrapolations and Emerging Updates for 2023-2027March 21, 2023 | marketwatch.comSee More Headlines MYOS Stock Analysis - Frequently Asked Questions How were MYOS RENS Technology's earnings last quarter? MYOS RENS Technology Inc. (NASDAQ:MYOS) issued its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.01. The company had revenue of $0.15 million for the quarter, compared to analysts' expectations of $0.14 million. MYOS RENS Technology had a negative trailing twelve-month return on equity of 166.68% and a negative net margin of 277.82%. What other stocks do shareholders of MYOS RENS Technology own? Based on aggregate information from My MarketBeat watchlists, some other companies that MYOS RENS Technology investors own include Chesapeake Energy (CHKAQ), Catalyst Pharmaceuticals (CPRX), Ampio Pharmaceuticals (AMPE), Biocept (BIOC), T2 Biosystems (TTOO), AbbVie (ABBV) and Global Blood Therapeutics (GBT). Company Calendar Last Earnings8/06/2019Today7/11/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:MYOS CIK1402479 Webwww.myosrens.com Phone(905) 812-0023FaxN/AEmployees15Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.26 million Net Margins-277.82% Pretax MarginN/A Return on Equity-166.68% Return on Assets-104.95% Debt Debt-to-Equity Ratio0.11 Current Ratio3.78 Quick Ratio1.94 Sales & Book Value Annual Sales$1.03 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / BookN/AMiscellaneous Outstanding Shares12,192,000Free FloatN/AMarket Cap$16.70 million OptionableNot Optionable Beta1.08 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:MYOS) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MYOS RENS Technology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MYOS RENS Technology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MYOS Stock Alerts